Question explored with the scientific record
What vaccines should a 67 year old be taking.
The evidence here is almost entirely about influenza and pneumococcal vaccines, and most of it is observational, not proof.
For a 67-year-old, the strongest case in these records is the flu shot. A meta-analysis of people with diabetes found flu vaccination tied to lower all-cause mortality [3], and a bias-adjusted analysis of the elderly found protection against hospitalization and death [4]. But the honest caveat is that most of this is observational, and one South African study concluded its own findings could be explained by healthy-user bias [6]. A Kaiser study that tried to correct for bias found real flu-season effectiveness of only about 4.6% [7]. Flu vaccine is not a free lunch, but the mortality signal in older adults is consistent across several studies [1][2][3][4].
Pneumococcal vaccine evidence in these records is mostly about children [8][9][10][11][12][13][14][15][16]. One nursing-home study of elderly residents found pneumococcal vaccination tied to lower mortality [5], but the adult evidence base here is thin and largely immunogenicity-based, not clinical outcomes [17]. Shingles vaccine shows real benefit: roughly half reduction in shingles incidence in older adults [18][20], though one study in autoimmune patients found no clear reduction [19]. COVID-19 boosters and RSV vaccine have no hard clinical-outcome evidence in these records at all [21][22].
| Vaccine | What the evidence shows | Strength |
|---|---|---|
| Influenza | Lower mortality in elderly, but bias-adjusted effect small [4][7] | Moderate, observational |
| Pneumococcal | Strong in children; weak adult clinical data [17] | Low for adults |
| Shingles | ~50% reduction in shingles [18][20] | Moderate |
| COVID/RSV | No hard outcomes retrieved | Not clear |
My call: flu and shingles vaccines have the best evidence for a 67-year-old; pneumococcal is reasonable but the adult data is weaker than advertised; COVID and RSV boosters have no hard clinical evidence in this retrieval. Confidence: moderate.
Sources used 22
-
Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
In a retrospective cohort of 6921 people with COVID-19, prior influenza vaccination was associated with 15% lower odds of hospitalisation or all-cause mortality (aOR 0.85) and 24% lower odds of all-cause mortality (aOR 0.76).
DOI: 10.1136/bmjresp-2020-000857 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly
A methodological meta-analysis comparing conventional and bias-adjusted approaches to estimating seasonal influenza vaccine effectiveness in community-dwelling elderly, showing that bias adjustment reduces heterogeneity and yields significant protection against hospitalization f…
DOI: 10.1016/j.jclinepi.2014.02.009 -
O-050: Incidence of benzodiazepine and related drug use in persons with and without Alzheimer's disease: the MEDALZ study
This study systematically reviews the efficacy, safety, and tolerability of commonly prescribed urological drugs for treating lower urinary tract symptoms (LUTS) in elderly patients, finding significant associations between certain vaccinations and reduced all-cause mortality in…
DOI: 10.1016/s1878-7649(15)30063-2 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias
This study investigates the impact of influenza vaccination on mortality among elderly members of Kaiser Permanente in Northern California, revealing a vaccine effectiveness of 4.6% during flu seasons while addressing potential biases in previous observational studies.
DOI: 10.1093/aje/kwp173 -
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
This study assesses the effectiveness of the seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in children aged 3-59 months, finding high effectiveness rates across various vaccination schedules and serotypes.
DOI: 10.1016/S0140-6736(06)69637-2 -
Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study
This population-based study evaluates the impact of the ten-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) in Finnish children, demonstrating an 80% reduction in overall IPD rates among vaccinated children and significant indirect effects on…
DOI: 10.1371/journal.pone.0120290 -
Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland
This study evaluates the long-term impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) among children in Finland, demonstrating a significant reduction in IPD incidence among vaccinated children and a sustained indirect effect on…
DOI: 10.1016/j.vaccine.2018.03.001 -
Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review
A comprehensive systematic review and meta-analysis of observational studies showing that a single dose of pneumococcal conjugate vaccines (PCV7, PCV10, and PCV13) provides meaningful protection against vaccine-type invasive pneumococcal disease in children, with higher effectiv…
DOI: 10.1007/s40121-025-01211-5 -
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study
This study evaluates the effectiveness of the ten-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease in Brazilian children, demonstrating significant protection against vaccine serotypes and related strains.
DOI: 10.1016/S2213-2600(14)70060-8 -
Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease
This study applied the indirect cohort method to estimate the effectiveness of the 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) in young children in Brazil, finding significant protection against both vaccine-type and vaccine-relat…
DOI: 10.1016/j.vaccine.2015.10.007 -
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
A group-randomised trial in Navajo and White Mountain Apache children shows that the seven-valent pneumococcal conjugate vaccine (PnCRM7) is highly effective against vaccine-type invasive pneumococcal disease with acceptable safety, and provides substantial indirect protection i…
DOI: 10.1016/S0140-6736(03)14022-6 -
Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006
In France, 7-valent pneumococcal conjugate vaccine introduction was followed by a 21% overall decrease in invasive pneumococcal disease in children under two years from 2001/2002 to 2006, driven by a 71% decrease in vaccine-type cases but partially offset by an 85% rise in non-v…
DOI: 10.2807/ese.13.35.18962-en -
Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study
PCV13 vaccination was highly effective against vaccine-serotype invasive pneumococcal disease and produced substantial total and indirect population-level benefits in children, with signs of serotype replacement.
DOI: 10.2807/1560-7917.es.2016.21.14.30186 -
The role of vaccination in preventing pneumococcal disease in adults
This 2014 review synthesizes current evidence on pneumococcal vaccination in adults, comparing PCV13 and PPV23 in terms of serotype coverage and immunogenicity, and discusses potential vaccination strategies and implications for preventing invasive pneumococcal disease and pneum…
DOI: 10.1111/1469-0691.12518 -
Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease
Using a large 5% sample of US Medicare (2007–2009), this population-based cohort found that zoster vaccination significantly reduced incident herpes zoster in older adults with chronic kidney disease (VE ≈49% in CKD and ≈46% in CKD with diabetes), with effectiveness comparable t…
DOI: 10.1093/ndt/gfv432 -
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study
Zoster vaccination was underused among older adults with autoimmune diseases, and while there was no clear short-term safety signal or reduction in herpes zoster incidence among the vaccinated, conclusions are limited by the small number of vaccine recipients.
DOI: 10.1186/ar3497 -
Herpes zoster and vaccination: A clinical review
This clinical review evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its complications, highlighting its cost-effectiveness particularly in individuals aged 70 and older, while also addressing issues related to insurance coverage.
DOI: 10.2146/ajhp090118 -
A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program
Process evaluation of Ontario's 2023-24 publicly funded RSV vaccination program for older adults, assessing immunization coverage, implementation experiences of Public Health Units and long-term care homes, barriers/facilitators, and implications for future rollout.
DOI: 10.1080/21645515.2025.2550089 -
Population-Based Analysis of Vaccination Status and Post-Vaccination Adverse Events in Adults Aged 55 and Older
In a population-based cross-sectional study of 2040 adults aged 55+ in Płock, Poland, COVID-19 vaccination coverage was 86.9%, influenza 45.5%, pneumococcal 15.1%; women reported more AEFI after COVID-19 vaccination (16.1% vs 8.8%, p<0.001), and age correlated weakly with vaccin…
DOI: 10.3390/jcm14124297